Category PRECISION MEDICINE

Combination therapy significantly improves outcomes for patients with metastatic colorectal cancer

Combining immune-targeted therapy with chemotherapy improves both progression-free survival and overall survival when compared to those who received regorafenib alone A study(Link is external) (Link opens in new window) led by UCLA Health Jonsson Comprehensive Cancer Center(Link opens in new window) researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival

Read More


FDA approves immunotherapy drug combo for non-muscle invasive bladder cancer after UCLA-led research shows improved outcomes for patients

Approval is based on findings from the QUILT 3.032 clinical trial, which was led by UCLA’s Dr. Karim Chamie The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy Bacillus Calmette-Guerin (BCG) for the treatment of

Read More


Clinical benefit for metastatic prostate cancer of Novartis Pluvicto™

Novartis presented data from the Phase III PSMAfore trial at the 2023 European Society for Medical Oncology (ESMO) Congress. Data presented at the Presidential Symposium showed that Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival (rPFS) in patients with prostate-specific membrane antigen

Read More


Researchers Design Gene Therapy That Can Effectively Target Glioblastoma

Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months. Immunotherapies, which mobilize the body’s immune defenses against a cancer, have not been effective for GBM, in part because the tumor’s surrounding environment is largely impenetrable to assaults from the body’s immune system.

Read More


New therapy harnesses patients’ blood cells to fight tumors

Noninvasive approach is fast, cost-effective and could be used to treat a variety of cancers doptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies

Read More


BWH Scientists Develop ‘Off the Shelf’ Engineered Stem Cells to Treat Aggressive Glioblastoma

Glioblastomas (GBMs) are highly aggressive cancerous tumors of the brain and spinal cord. Brain cancers like GBM are challenging to treat because many cancer therapeutics cannot pass through the blood-brain barrier, and more than 90 percent of GBM tumors return after being surgically removed, despite surgery and subsequent chemo- and radiation therapy being the most

Read More


ALY101 molecule holds promise in potential therapies for cancer and rare diseases

Researchers at the University of California, Irvine and the Italian Institute of Technology have developed a new molecule, ALY101, that shows promising anti-cancer activity against a wide range of tumor cell types and in mouse models of a common type of melanoma. The findings, “Structure-based Design of CDC42 Effector Interaction Inhibitors for the Treatment of

Read More


Coagulation proteases and Direct Oral Anticoagulants impact on cancer growth and metastasis

The hemostatic system in cancer The hemostatic system forms an integral part of the innate immune system and contributes to tumor growth and metastasis. Many malignancies are associated with a hyper-thrombotic state that derives foremost from tissue factor (TF), the initiator of the coagulation cascade, expressed by tumor cells and innate immune cells and stromal

Read More